TITLE

Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients

AUTHOR(S)
Eaddy, Michael; Seal, Brian; Tangirala, Muralikrishna; Davies, Elizabeth Hackney; O'Day, Ken
PUB. DATE
December 2010
SOURCE
American Journal of Health-System Pharmacy;12/15/2010, Vol. 67 Issue 24, p2110
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. Economic outcomes of rasburicase and allopurinol for treatment of tumor lysis syndrome (TLS) in pediatric patients were compared. Methods. Claims data from a large hospital database were used to conduct the analysis. Pediatric patients diagnosed with TLS and administered rasburicase or allopurinol within two days of hospital admission were eligible for inclusion. Patients were excluded if they were age .18 years or received hemodialysis on admission. Patients receiving rasburicase were propensity score matched to allopurinol-treated patients based on sex, race, hospital type, provider type, payer type, admission source, use of electrolyte modification therapy, and comorbid diagnoses. Differences in health care costs, length of stay (LOS), and duration of subsequent critical care were assessed using g-distributed generalized linear models with a log-link function. Results. A total of 63 allopurinol-treated and 63 rasburicase-treated patients were matched in the analysis. The mean age of patients was 7.4 years, and girls comprised 27% of the sample. Rasburicase-treated patients incurred a mean cost of $30,470 per hospitalization, compared with $35,165 for allopurinol-treated patients (p = 0.427). Duration of critical care was significantly shorter for rasburicase-treated patients (1.4 days versus 2.5 days for allopurinol-treated patients, p = 0.0001); however, mean LOS did not statistically differ between groups, averaging 13.8 days for patients treated with rasburicase and 14.9 days for the allopurinol-treated group. Conclusion. Examination of claims from a large hospital database showed that treatment with rasburicase, compared with allopurinol, was associated with a significant reduction in critical care days but not with a significant difference in mean LOS or total cost.
ACCESSION #
56586824

 

Related Articles

  • It pays to use rasburicase for TLS.  // PharmacoEconomics & Outcomes News;6/13/2009, Issue 580, p9 

    This section discusses two research on tumor lysis syndrome (TLS), presented at the 45th Annual Meeting of the American Society of Clinical Oncology. One study examined the use of rasburicase alone or combined with allopurinol in patients with TLS. The other study included patients who were...

  • Rasburicase.  // Reactions Weekly;Oct2015, Vol. 1571 Issue 1, p206 

    The article presents case report of a patient who developed methaemoglobinaemia during treatment with rasburicase for tumor lysis syndrome (TLS).

  • Role of i.v.allopurinol and rasburicase in tumor lysis syndrome.  // American Journal of Health-System Pharmacy;11/1/2003, Vol. 60 Issue 21, p2223 

    Presents information about the role of developed drugs, i.v.allopurinol and rasburicase in tumor lysis syndrome. Information regarding the origins and limitations of standard therapy for the prevention of the disease; Effects of the drugs in the treatment of the disease; Comparison with other...

  • Cost-effectiveness of rasburicase over i.v. allopurinol for treatment of tumor lysis syndrome. Patel, Samit; Le, Ann; Gascon, Sunshine // American Journal of Health-System Pharmacy;6/15/2012, Vol. 69 Issue 12, p1015 

    A letter to the editor is presented which discusses the cost-effectiveness of rasburicase versus intravenous (i.v.) allopurinol as the most effective treatment for hyperuricemia associated with tumor lysis syndrome (TLS).

  • Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.  // Journal of Oncology Pharmacy Practice;Sep2010, Vol. 16 Issue 3, p205 

    The article discusses research investigating the use of rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome (TLS). Topics include an overview of the research methodology, which involved a review of TLS literature and metabolic imbalances, such as hyperuricemia,...

  • Miscellaneous.  // Current Medical Literature: Leukemia & Lymphoma;2011, Vol. 19 Issue 1, p25 

    The article discusses several studies relating to leukemia and lymphoma. One study examined the clinical significance of the allelic level of the JAK2 V617F mutation in patients with polycythemia vera (PV). A multicenter registry study assessed a cohort of patients with a persistent...

  • Rasburicase: Clearing Uric Acid from the Tumor Lysis Syndrome. Ershler, William B. // Clinical Oncology Alert;Mar2011, Vol. 27 Issue 3, p19 

    The article discusses the safety and efficacy of using rasburicase (recombinant urate oxidase) for clearing uric acid in patients at high risk for tumor lysis syndrome (TLS) and children with leukemia and lymphoma. Pediatric and adult trials supporting the U.S. Food and Drug Administration's...

  • Acute renal failure from xanthine nephropathy during management of acute leukemia. LaRosa, Christopher; McMullen, Laura; Bakdash, Suzanne; Ellis, Demetrius; Krishnamurti, Lakshmanan; Hsi-Yang Wu; L. Moritz, Michael // Pediatric Nephrology;Jan2007, Vol. 22 Issue 1, p132 

    Tumor lysis syndrome is a potentially life-threatening complication of induction chemotherapy for treatment of lymphoproliferative malignancies. Serious complications of tumor lysis syndrome are rare with the preemptive use of allopurinol, rasburicase, and urine alkalinization. We report a case...

  • Tümör lizis sendromu; tanı, izlem ve tedavide yeni yaklaşımlar. Celkan, Tiraje; Tüysüz, Gülen // Turkish Pediatrics Archive / Turk Pediatri Arsivi;sep2013, Vol. 48 Issue 3, p188 

    Tumor lysis syndrome is a clinical situation which occurs with the lysis of malignant cells and causes metabolic abnormalities that threatens life. These metabolic abnormalities are caused by the release of intracellular ions, nucleic acids, proteins and their metabolites from the instant...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics